NCT07432607 (HIFI-NIVATS) is a NA clinical trial of High-Flow Nasal Oxygen Therapy (HFNOT) in Hypoxemia During Surgery, sponsored by Ebru Girgin Dinc.

Who is sponsoring NCT07432607?

NCT07432607 is sponsored by Ebru Girgin Dinc.

What drugs are being tested in NCT07432607?

Interventions in NCT07432607: High-Flow Nasal Oxygen Therapy (HFNOT), Conventional Oxygen Mask (COM).

What condition does NCT07432607 study?

NCT07432607 studies Hypoxemia During Surgery.

Is NCT07432607 still recruiting?

NCT07432607 is currently recruiting now. Last updated 3 May 2026.

Last reviewed 2026-05-03 · How we verify

NCT07432607: HIFI-NIVATS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimizing Oxygen Delivery During Sedoanalgesia for Video-Assisted Thoracoscopic Pericardial Window: High-Flow Nasal Oxygen vs. Face Mask Oxygenation, A Prospective Comparative Study

Recruiting now NA Last updated 3 May 2026

What this trial tests

NA trial testing High-Flow Nasal Oxygen Therapy (HFNOT) in Hypoxemia During Surgery in 60 participants. Currently enrolling.

Timeline

1 June 2025

Primary endpoint
30 December 2026

1 February 2027

Quick facts

Lead sponsor	Ebru Girgin Dinc
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	supportive care
Enrollment	60
Start date	1 June 2025
Primary completion	30 December 2026
Estimated completion	1 February 2027
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

High-Flow Nasal Oxygen Therapy (HFNOT)
Conventional Oxygen Mask (COM)

Conditions studied

Hypoxemia During Surgery — all drugs for Hypoxemia During Surgery →

Sponsor

Ebru Girgin Dinc

Who can join

Adults 18 to 75, any sex, with Hypoxemia During Surgery. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Oxygen Saturation Trends
Time frame: Up to postoperative 30 minutes
Oxygen Saturation Ratio (%)

Sponsor's own description

This is a prospective, randomized, parallel-group clinical trial designed to evaluate the effects of high-flow nasal oxygen therapy (HFNOT) versus conventional oxygen mask (COM) on perioperative hypoxia in patients undergoing video-assisted thoracoscopic (VATS) pericardial window procedures under sedoanalgesia. The pericardial window procedure, indicated for diagnostic and therapeutic drainage of pericardial effusion, is traditionally performed under general anesthesia. However, the use of non-intubated VATS with sedoanalgesia has gained popularity due to reduced morbidity, shorter recovery, and avoidance of complications associated with general anesthesia, especially in elderly and comorbid patients. During non-intubated VATS, the occurrence of hypoxia and hemodynamic instability may be exacerbated by procedural pneumothorax and underlying cardiac pathology. High-flow nasal oxygen therapy may provide physiological benefits in this setting by reducing airway resistance, improving alveolar ventilation, and minimizing dead space. The primary outcome of the study is to compare the incidence of perioperative hypoxia between HFNOT and COM groups. Secondary outcomes include patient comfort, intraoperative oxygenation profiles, hemodynamic stability, and recovery parameters. The trial will be conducted at a single academic center with eligible patients randomized into two treatment arms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Ebru Girgin Dinc trials

Trials by the same sponsor.

NCT07293273 — Procedural Sedation in Renal Sympathetic Denervation · completed
NCT07132619 — Kidney Injury After PTE: Association With Hypothermic Circulatory Arrest Duration · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07432607 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ebru Girgin Dinc
Last refreshed: 3 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07432607.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing